CARA, INSY, and GWPH: Analysts’ Recommendations in January

Stock performance

On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close and ~14% YTD (year-to-date) growth. The company’s closing price also represents an ~39% discount over its 52-week high of $24.30 on September 21 and ~29% growth from its 52-week low of $11.46 on April 3.

On January 28, INSYS Therapeutics’ stock price closed at $3.5, which is an ~8.14% discount compared to its previous close. The company’s closing price is an ~4% premium over its 52-week low of $3.35 on December 28 and an ~70% discount over its 52-week high of $11.65 on August 30.

CARA, INSY, and GWPH: Analysts’ Recommendations in January

GW Pharmaceuticals’ (GWPH) stock price closed at $138.07 on January 28, which is an ~0.35% decline from its previous close. The company’s closing price represents an ~53% premium compared to its 52-week low of $90.14 on December 27 and an ~23% discount over its 52-week high of $179.65 on September 27.

According to the closing price on January 28, GW Pharmaceuticals stock grew ~42% YTD in January. Cara Therapeutics stock grew ~14%, while INSYS Therapeutics stock remained flat.

Analysts’ recommendations

In January, among the ten analysts tracking Cara Therapeutics, four recommended a “strong buy,” five recommended a “buy,” and one recommended a “hold” rating.

Among the six analysts tracking INSYS Therapeutics, two recommended a “strong buy,” three recommended a “buy,” and one recommended a “sell” rating.

Among the 12 analysts tracking GW Pharmaceuticals, three recommended a “strong buy,” eight recommended a “buy,” and one recommended a “hold” rating.

On January 29, Cara Therapeutics, INSYS Therapeutics, and GW Pharmaceuticals had a consensus 12-month target price of $26.1, $8.5, and $173.17, respectively, which represents an ~76.11%, ~142.86%, and ~25.42% return on investment over the next 12 months.